chr17-70175691-C-T
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000891.3(KCNJ2):c.652C>T(p.Arg218Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R218Q) has been classified as Pathogenic.
Frequency
Consequence
NM_000891.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:6
- -
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Functional studies demonstrate a damaging effect: the variant causes a loss of function and a dominant negative effect on channel function when expressed with the wild-type protein (Plaster et al., 2001; Lange et al. 2003; Caballero et al., 2010); Also known as Kir2.1; This variant is associated with the following publications: (PMID: 12163457, 17568571, 17211524, 23631430, 20647529, 11371347, 25415519, 23867365, 15269659, 17119796, 18554214, 28501311, 12796536, 17221872, 22589293, 29093808, 15852530, 16217063, 17399642, 22581653, 28024840, 31068157, 31567646, 34008892, 35460302, 33057326, 20713726, 12909315) -
- -
- -
- -
- -
Andersen Tawil syndrome Pathogenic:4Other:1
- -
- -
- -
PM2, PM5, PP2, PP3, PP4, PP5 -
The identified mutation leads to the substitution of Arginine 218 with Tryptophan (R218W) in the KCNJ2 protein. Hence, this substitution alters the amino acid sequence and leads to a missense mutation at position 218 with possible increased function in the mutated protein. -
Andersen Tawil syndrome;C1865018:Short QT syndrome type 3;C3151431:Atrial fibrillation, familial, 9 Pathogenic:1
PM2_Supporting+PP3_Moderate+PP2+PS4+PM6_Supporting+PP1_Strong -
Andersen Tawil syndrome;C1865018:Short QT syndrome type 3 Pathogenic:1
This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 218 of the KCNJ2 protein (p.Arg218Trp). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Andersen-Tawil syndrome (PMID: 12796536, 17119796, 17221872, 22589293). In at least one individual the variant was observed to be de novo. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 8919). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt KCNJ2 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects KCNJ2 function (PMID: 12909315, 17119796, 17568571). For these reasons, this variant has been classified as Pathogenic. -
Cardiovascular phenotype Pathogenic:1
The p.R218W pathogenic mutation (also known as c.652C>T), located in coding exon 1 of the KCNJ2 gene, results from a C to T substitution at nucleotide position 652. The arginine at codon 218 is replaced by tryptophan, an amino acid with dissimilar properties. This variant has been reported in multiple individuals with features consistent with Andersen-Tawil syndrome (ATS), including de novo occurrences, has been reported to segregate with disease features in families, and has shown intrafamilial phenotypic variability (Plaster NM et al. Cell. 2001 May;105(4):511-9; Donaldson MR et al. Neurology. 2003 Jun;60(11):1811-6; Tengan CH et al. Arq Neuropsiquiatr. 2006 Sep;64(3A):582-4; Haruna Y et al. Hum Mutat. 2007 Feb;28(2):208; Kimura H et al. Circ Cardiovasc Genet. 2012 Jun;5(3):344-53; Lefter S et al. J Clin Neuromuscul Dis. 2014 Dec;16(2):79-82; Ardissone A et al. Neuromuscul Disord. 2017 Mar;27(3):294-297; Villar-Quiles RN et al. Eur J Neurol. 2022 Aug;29(8):2398-2411). Another variant at the same codon, p.R218Q (c.653G>A), has also been reported in association with ATS (Plaster NM et al. Cell, 2001 May;105:511-9). In assays testing KCNJ2 function, this variant showed functionally abnormal results (Plaster NM. Cell. 2001 May;105(4):511-9; Lange PS. Cardiovasc Res. 2003 Aug;59(2):321-7). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. -
Congenital long QT syndrome Other:1
This variant has been reported in the following publications (PMID:11371347;PMID:12163457;PMID:12796536;PMID:15852530;PMID:16217063;PMID:17074642;PMID:17119796;PMID:17221872;PMID:17399642;PMID:18554214;PMID:20647529). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at